Algert Global LLC Buys 59,850 Shares of Phibro Animal Health Co. (NASDAQ:PAHC)

Algert Global LLC raised its stake in shares of Phibro Animal Health Co. (NASDAQ:PAHC) by 521.1% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 71,335 shares of the company’s stock after purchasing an additional 59,850 shares during the quarter. Algert Global LLC’s holdings in Phibro Animal Health were worth $1,606,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in PAHC. Segall Bryant & Hamill LLC grew its position in Phibro Animal Health by 1.7% during the third quarter. Segall Bryant & Hamill LLC now owns 174,569 shares of the company’s stock worth $3,931,000 after buying an additional 2,971 shares in the last quarter. Thrivent Financial for Lutherans grew its holdings in shares of Phibro Animal Health by 23.1% during the 3rd quarter. Thrivent Financial for Lutherans now owns 20,791 shares of the company’s stock worth $468,000 after purchasing an additional 3,907 shares in the last quarter. Pinnacle Associates Ltd. increased its holdings in Phibro Animal Health by 18.8% in the 3rd quarter. Pinnacle Associates Ltd. now owns 24,120 shares of the company’s stock valued at $543,000 after buying an additional 3,820 shares during the period. China Universal Asset Management Co. Ltd. increased its stake in Phibro Animal Health by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,912 shares of the company’s stock valued at $88,000 after acquiring an additional 1,522 shares during the period. Finally, Cardinal Capital Management grew its stake in shares of Phibro Animal Health by 16.0% in the 3rd quarter. Cardinal Capital Management now owns 64,986 shares of the company’s stock valued at $1,463,000 after purchasing an additional 8,959 shares during the period. Institutional investors and hedge funds own 99.34% of the company’s stock.

Phibro Animal Health Stock Performance

Phibro Animal Health stock opened at $23.59 on Thursday. The stock has a 50-day simple moving average of $23.27 and a 200 day simple moving average of $20.14. The stock has a market capitalization of $955.40 million, a price-to-earnings ratio of 54.86, a P/E/G ratio of 0.62 and a beta of 0.51. The company has a quick ratio of 1.69, a current ratio of 3.23 and a debt-to-equity ratio of 1.81. Phibro Animal Health Co. has a 12-month low of $9.49 and a 12-month high of $25.98.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Wednesday, August 28th. The company reported $0.41 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.07. Phibro Animal Health had a net margin of 1.67% and a return on equity of 21.59%. The company had revenue of $273.16 million during the quarter, compared to the consensus estimate of $262.44 million. On average, research analysts anticipate that Phibro Animal Health Co. will post 1.61 earnings per share for the current fiscal year.

Phibro Animal Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 18th. Shareholders of record on Wednesday, November 27th will be issued a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a yield of 2.03%. The ex-dividend date is Wednesday, November 27th. Phibro Animal Health’s dividend payout ratio is 111.63%.

Insider Activity

In related news, Director E Thomas Corcoran purchased 5,000 shares of the stock in a transaction dated Wednesday, September 4th. The stock was bought at an average cost of $20.02 per share, with a total value of $100,100.00. Following the purchase, the director now directly owns 25,000 shares in the company, valued at $500,500. The trade was a 25.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. 50.07% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

PAHC has been the topic of several recent analyst reports. Barclays boosted their price target on Phibro Animal Health from $13.00 to $20.00 and gave the company an “underweight” rating in a research note on Tuesday, November 12th. StockNews.com upgraded shares of Phibro Animal Health from a “buy” rating to a “strong-buy” rating in a research report on Thursday. Bank of America boosted their price target on shares of Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a research report on Friday, August 30th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Phibro Animal Health in a report on Tuesday, September 10th. They set a “neutral” rating and a $22.00 price objective for the company. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Phibro Animal Health currently has a consensus rating of “Hold” and a consensus price target of $16.50.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.